Myasthenia gravis

A post-hoc analysis of the results of the Adapt trial, which was conducted in France in 167 adults with a generalised form of autoimmune myasthenia gravis, showed that efgartigimod resulted in : an improvement, greater than on placebo, in each of the muscle sub-domains (respiratory, ocular, bulbar, limb) assessed by the MG-ADL score, observed from … [Read more]

The role of intestinal flora is the subject of sustained attention in medical research, particularly in dysimmune diseases such as myasthenia gravis. Various publications point to the existence of dysbiosis in this disease: The results of the German Mybiom study show, in cases of myasthenia (n=42), a lower diversity of intestinal flora than in a … [Read more]

UCB and Sharecare conducted a three-month prospective real-life study in the United States involving 82 patients with moderate to severe autoimmune myasthenia gravis. The participants sent selfie videos to the investigators, which were analysed automatically by a margin reflex distance (MDR1) measurement tool developed using an artificial neural network: these measurements proved to be effective, … [Read more]

A retrospective study of the medical data of 493 people suffering from autoimmune myasthenia followed by the university hospital centres of Strasbourg, Lyon, Grenoble and Angers reveals that the disease began after the age of 70 for 28% of them. Among these older patients : 76% improved with treatment during follow-up, despite lower doses, 41% … [Read more]

A retrospective study of 859 patients followed by a Shanghai hospital for Myasthenia gravis diagnosed before the age of 14 found : an ocular form in 97.8% of cases, which only generalized in 14% of patients; 21.7% were in stable complete remission, 15.3% in pharmaceutical remission, and 42% of patients had achieved minimal manifestation status … [Read more]

A retrospective Canadian study of 80 people with double-seronegative myasthenia for anti-RACh and anti-MuSK antibodies, compared with 73 people with myasthenia for anti-RACh antibodies, showed that : the initial proportion of people with ocular forms (46.3%) was significantly higher in the double-seronegative group than in the anti-RACh myasthenia group; the Myasthenia Gravis Impairment Index (MGII) … [Read more]

The MG-001 trial is evaluating Descartes-08 CAR-T cells from Cartesian Therapeutics in the United States. These are autologous T lymphocytes genetically modified, not by DNA but by RNA, to target the B lymphocyte maturation antigen (BCMA) expressed on the surface of plasma cells. The first two parts of the trial, in 14 adults with a … [Read more]

Italian researchers have compiled recent data from the literature on the efficacy of new treatments for myasthenia gravis, in particular complement inhibitors and fetal immunoglobulin receptor (FcRn) blockers. A Cochrane-type approach was used, resulting in a simple meta-analysis and a network meta-analysis, The observation windows for product efficacy were significantly different (26 weeks for eculizumab … [Read more]